Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path
- COMPANION-002 Phase 2/3 data planned for FDA discussion before a potential BLA submission
- Complete COMPANION-002 dataset expected at a medical conference in 2026
- Regulatory pathway remains contingent on FDA interactions, clinical data, and additional funding needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.